Oxytocin in the heart regeneration.

Marek Jankowski, Araceli Gonzalez-Reyes, Nicolas Noiseux, Jolanta Gutkowska
{"title":"Oxytocin in the heart regeneration.","authors":"Marek Jankowski,&nbsp;Araceli Gonzalez-Reyes,&nbsp;Nicolas Noiseux,&nbsp;Jolanta Gutkowska","doi":"10.2174/157489012801227210","DOIUrl":null,"url":null,"abstract":"<p><p>We have demonstrated that entire oxytocin (OT) system is synthesized in the rat and human heart and this hormone is implicated in several cardiac functions including stem cells differentiation into cardiomyocytes. These observations led us to the invention of OT as an inducer of cardiomyogenesis (US20060205636A1). We also proposed the use of OT, its functional derivatives, and/or physiological precursors as well as nucleic acids capable of encoding OT as cell-differentiating and useful agents for treating or preventing diseases, such as heart diseases associated with loss of cardiomyocytes. The invention is relevant to the use of OT or OT-related compounds. OT is claimed as an inducer that promotes the differentiation of non-cardiomyocytes (e.g. stem/progenitor cells) in situ, which can be used to repair, restore or fortify damaged cardiac tissue or in cell culture in order to provide material for cell or tissue grafting in the heart. Recent reports documented the significant progress in the research on the role of OT in cardiovascular regulation. Most of the results are consistent with the postulated cardioprotective role of OT. In this review, new data are discussed in the context of the main points presented in the invention.</p>","PeriodicalId":20905,"journal":{"name":"Recent patents on cardiovascular drug discovery","volume":"7 2","pages":"81-7"},"PeriodicalIF":0.0000,"publicationDate":"2012-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2174/157489012801227210","citationCount":"11","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Recent patents on cardiovascular drug discovery","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/157489012801227210","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 11

Abstract

We have demonstrated that entire oxytocin (OT) system is synthesized in the rat and human heart and this hormone is implicated in several cardiac functions including stem cells differentiation into cardiomyocytes. These observations led us to the invention of OT as an inducer of cardiomyogenesis (US20060205636A1). We also proposed the use of OT, its functional derivatives, and/or physiological precursors as well as nucleic acids capable of encoding OT as cell-differentiating and useful agents for treating or preventing diseases, such as heart diseases associated with loss of cardiomyocytes. The invention is relevant to the use of OT or OT-related compounds. OT is claimed as an inducer that promotes the differentiation of non-cardiomyocytes (e.g. stem/progenitor cells) in situ, which can be used to repair, restore or fortify damaged cardiac tissue or in cell culture in order to provide material for cell or tissue grafting in the heart. Recent reports documented the significant progress in the research on the role of OT in cardiovascular regulation. Most of the results are consistent with the postulated cardioprotective role of OT. In this review, new data are discussed in the context of the main points presented in the invention.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
催产素在心脏再生中的作用。
我们已经证明,整个催产素(OT)系统是在大鼠和人类心脏中合成的,这种激素与多种心脏功能有关,包括干细胞向心肌细胞的分化。这些观察结果使我们发明了OT作为心肌形成的诱导剂(US20060205636A1)。我们还建议使用OT、其功能衍生物和/或生理前体以及能够编码OT的核酸作为细胞分化和治疗或预防疾病的有用药物,例如与心肌细胞损失相关的心脏病。本发明涉及OT或OT相关化合物的使用。OT被认为是促进非心肌细胞(如干细胞/祖细胞)原位分化的诱导剂,可用于修复、恢复或强化受损的心脏组织或细胞培养,以便为心脏中的细胞或组织移植提供材料。最近的报道证明了OT在心血管调节中的作用的研究取得了重大进展。大多数结果与OT的心脏保护作用的假设一致。在这篇综述中,新的数据在本发明提出的主要观点的背景下进行了讨论。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Patents and Heart Valve Surgery - III: Percutaneous Heart Valves. Patents and Heart Valve Surgery - III: Percutaneous Heart Valves. New frontiers in the management of acute coronary syndromes: cangrelor and elinogrel. Blockade of renin angiotensin system in heart failure post-myocardial infarction: what is the best therapy? Ticagrelor: a novel drug for an old problem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1